相似文献
1
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
Curr Protoc Microbiol. 2020 Sep;58(1):e108. doi: 10.1002/cpmc.108.
2
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
Nat Commun. 2020 Oct 15;11(1):5214. doi: 10.1038/s41467-020-19055-7.
3
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
J Virol Methods. 2021 Jan;287:113995. doi: 10.1016/j.jviromet.2020.113995. Epub 2020 Oct 14.
4
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6. doi: 10.1016/j.chom.2020.06.020. Epub 2020 Jul 3.
5
Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5. doi: 10.1016/j.chom.2020.06.021. Epub 2020 Jul 3.
6
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
J Exp Med. 2020 Nov 2;217(11). doi: 10.1084/jem.20201181.
7
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
8
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Nature. 2020 Aug;584(7819):120-124. doi: 10.1038/s41586-020-2381-y. Epub 2020 May 26.
9
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
10
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.
Indian J Med Res. 2020;152(1 & 2):82-87. doi: 10.4103/ijmr.IJMR_2382_20.
引用本文的文献
1
Survival and transmission fitness of SARS-CoV-2 over the time-of-flight in an aerosolization chamber.
Npj Viruses. 2025 Aug 18;3(1):61. doi: 10.1038/s44298-025-00143-8.
2
Characterization of the Binding and Inhibition Mechanisms of a Novel Neutralizing Monoclonal Antibody Targeting the Stem Helix Region in the S2 Subunit of the Spike Protein of SARS-CoV-2.
Vaccines (Basel). 2025 Jun 26;13(7):688. doi: 10.3390/vaccines13070688.
3
Lipid Nanoparticle Development for A Fluvid mRNA Vaccine Targeting Seasonal Influenza and SARS-CoV-2.
NPJ Vaccines. 2025 Jun 11;10(1):123. doi: 10.1038/s41541-025-01153-6.
4
Addressing SARS-CoV-2 evolution: neutralization of emerging variants of concern by the AVX/COVID-12 'Patria' vaccine based on HexaPro-S ancestral Wuhan spike or its updated BA.2.75.2 version.
Front Immunol. 2025 May 19;16:1565934. doi: 10.3389/fimmu.2025.1565934. eCollection 2025.
5
Automated and virus variant-programmable surrogate test qualitatively compares to the gold standard SARS-CoV-2 neutralization assay.
Npj Viruses. 2024 Dec 30;2(1):68. doi: 10.1038/s44298-024-00083-9.
6
5,6-dihydroxyflavone exerts anti-betacoronavirus activity by blocking viral entry to host cells.
Virus Res. 2025 Jun;356:199578. doi: 10.1016/j.virusres.2025.199578. Epub 2025 Apr 23.
7
Human Source Severe Acute Respiratory Syndrome Coronavirus 2 Aerosol Transmission to Remote Sentinel Hamsters.
Open Forum Infect Dis. 2025 Apr 1;12(4):ofaf196. doi: 10.1093/ofid/ofaf196. eCollection 2025 Apr.
8
Discovery of Nanosota-9 as anti-Omicron nanobody therapeutic candidate.
PLoS Pathog. 2024 Nov 26;20(11):e1012726. doi: 10.1371/journal.ppat.1012726. eCollection 2024 Nov.
9
Dual Functionality of Papaya Leaf Extracts: Anti-Coronavirus Activity and Anti-Inflammation Mechanism.
Foods. 2024 Oct 16;13(20):3274. doi: 10.3390/foods13203274.
10
Development of a new experimental NMR strategy for covalent cysteine protease inhibitors screening: toward enhanced drug discovery.
RSC Adv. 2024 Aug 23;14(37):26829-26836. doi: 10.1039/d4ra04938a. eCollection 2024 Aug 22.
本文引用的文献
1
The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Cell. 2020 Aug 6;182(3):685-712.e19. doi: 10.1016/j.cell.2020.06.034. Epub 2020 Jun 28.
2
Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2.
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105. doi: 10.1002/cpmc.105.
3
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
4
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
5
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients.
Emerg Infect Dis. 2020 Jul;26(7):1478-1488. doi: 10.3201/eid2607.200841. Epub 2020 Jun 21.
6
SARS-CoV-2 Vaccines: Status Report.
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.
7
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.
8
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses.
Nat Microbiol. 2020 Apr;5(4):562-569. doi: 10.1038/s41564-020-0688-y. Epub 2020 Feb 24.
9
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Science. 2020 Mar 13;367(6483):1260-1263. doi: 10.1126/science.abb2507. Epub 2020 Feb 19.
10
A new coronavirus associated with human respiratory disease in China.
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
Zotero 插件